69 related articles for article (PubMed ID: 17546603)
1. Effects of tyroserleutide on gene expression of calmodulin and PI3K in hepatocellular carcinoma.
Zhao L; Zhao Q; Lu R; Fu Z; Zhu Z; Jia J; Wang S; Shi L; Jian X; Yao Z
J Cell Biochem; 2008 Feb; 103(2):471-8. PubMed ID: 17546603
[TBL] [Abstract][Full Text] [Related]
2. Effects of Tyroserleutide on phosphatidylinositol 3'-kinase/AKT pathway in human hepatocellular carcinoma cell.
Fu Z; Ren L; Wei H; Lv J; Che X; Zhu Z; Jia J; Wang L; Lin G; Lu R; Yao Z
J Drug Target; 2014 Feb; 22(2):146-55. PubMed ID: 24147456
[TBL] [Abstract][Full Text] [Related]
3. A novel tripeptide, tyroserleutide, inhibits irradiation-induced invasiveness and metastasis of hepatocellular carcinoma in nude mice.
Jia JB; Wang WQ; Sun HC; Liu L; Zhu XD; Kong LQ; Chai ZT; Zhang W; Zhang JB; Xu HX; Zeng ZC; Wu WZ; Wang L; Tang ZY
Invest New Drugs; 2011 Oct; 29(5):861-72. PubMed ID: 20414698
[TBL] [Abstract][Full Text] [Related]
4. Effects of a novel tripeptide, tyroserleutide (YSL), on cell cycle progression of human hepatocellular carcinoma.
Wang C; Wang S; Lu R; Zhao L; Zhu ZF; Xu Q; Lv JQ; Wang LL; Fu Z; Lin G; Yao Z
Anticancer Drugs; 2009 Aug; 20(7):534-42. PubMed ID: 19491661
[TBL] [Abstract][Full Text] [Related]
5. Expression of PTEN, p27, p21 and AKT mRNA and protein in human BEL-7402 hepatocarcinoma cells in transplanted tumors of nude mice treated with the tripeptide tyroservatide (YSV).
Zhu Z; Jia J; Lu R; Lu Y; Fu Z; Zhao L; Wang L; Jin M; Zhao L; Gao W; Yao Z
Int J Cancer; 2006 Mar; 118(6):1539-44. PubMed ID: 16184552
[TBL] [Abstract][Full Text] [Related]
6. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF
Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542
[TBL] [Abstract][Full Text] [Related]
7. Tyroserleutide tripeptide affects calcium homeostasis of human hepatocarcinoma BEL-7402 cells.
Fu Z; Lu R; Li G; Zhao L; Gao W; Che X; Jian X; Zhou C; Yao Z
Sci China C Life Sci; 2005 Oct; 48(5):523-30. PubMed ID: 16315604
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of tyroserleutide on lung metastasis of human hepatocellular carcinoma SK-HEP-1 and its mechanism affecting ICAM-1 and MMP-2 and -9.
Che X; Lu R; Fu Z; Sun Y; Zhu ZF; Li JP; Wang S; Jia J; Wang Q; Yao Z
Drug Des Devel Ther; 2018; 12():3357-3368. PubMed ID: 30349190
[TBL] [Abstract][Full Text] [Related]
9. The effect of tripeptide tyroserleutide (YSL) on animal models of hepatocarcinoma.
Yao Z; Lu R; Jia J; Zhao P; Yang J; Zheng M; Lu J; Jin M; Yang H; Gao W
Peptides; 2006 Jun; 27(6):1167-72. PubMed ID: 16129512
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the inhibitory effect of tripeptide tyroservatide on growth of human hepatocellular carcinoma using a hollow fiber assay].
Shi LX; Lu R; Wang L; Zhou CL; Xu Q; Zhu ZF; Ma R; Zhang HL; Jia J; Fu Z; Yao Z
Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):725-8. PubMed ID: 19173797
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate.
Svechnikova I; Gray SG; Kundrotiene J; Ponthan F; Kogner P; Ekström TJ
Int J Oncol; 2003 Mar; 22(3):579-88. PubMed ID: 12579311
[TBL] [Abstract][Full Text] [Related]
12. FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.
Zhou JD; Shen F; Ji JS; Zheng K; Huang M; Wu JC
Oncol Rep; 2013 Sep; 30(3):1275-84. PubMed ID: 23836295
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the therapeutic efficacy of tripeptide tyroserleutide (YSL) for human hepatocarcinoma by in vivo hollow fiber assay.
Li XL; Liu JY; Lu R; Xu Q; Zhu ZF; Wang L; Zhou CL; Jia J; Fu Z; Yao Z
Invest New Drugs; 2008 Dec; 26(6):525-9. PubMed ID: 18264678
[TBL] [Abstract][Full Text] [Related]
14. Pivotal role of mTOR signaling in hepatocellular carcinoma.
Villanueva A; Chiang DY; Newell P; Peix J; Thung S; Alsinet C; Tovar V; Roayaie S; Minguez B; Sole M; Battiston C; Van Laarhoven S; Fiel MI; Di Feo A; Hoshida Y; Yea S; Toffanin S; Ramos A; Martignetti JA; Mazzaferro V; Bruix J; Waxman S; Schwartz M; Meyerson M; Friedman SL; Llovet JM
Gastroenterology; 2008 Dec; 135(6):1972-83, 1983.e1-11. PubMed ID: 18929564
[TBL] [Abstract][Full Text] [Related]
15. Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation.
Zhu ZF; Chen LJ; Lu R; Jia J; Liang Y; Xu Q; Zhou CL; Wang L; Wang S; Yao Z
BMC Cancer; 2008 Nov; 8():342. PubMed ID: 19025669
[TBL] [Abstract][Full Text] [Related]
16. A synthetic peptide hijacks the catalytic subunit of class I PI3K to suppress the growth of cancer cells.
Guo W; You X; Wang X; Wang L; Chen Y
Cancer Lett; 2017 Oct; 405():1-9. PubMed ID: 28743532
[TBL] [Abstract][Full Text] [Related]
17. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Rychahou PG; Jackson LN; Silva SR; Rajaraman S; Evers BM
Ann Surg; 2006 Jun; 243(6):833-42; discussion 843-4. PubMed ID: 16772787
[TBL] [Abstract][Full Text] [Related]
18. Experimental study of the inhibition of human hepatocarcinoma Bel7402 cells by the tripeptide tyroserleutide(YSL).
Lu R; Jia J; Bao L; Fu Z; Li G; Wang S; Wang Z; Jin M; Gao W; Yao Z
Cancer Chemother Pharmacol; 2006 Jan; 57(2):248-56. PubMed ID: 16028100
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor and anti-angiogenic effects of manumycin on human hepatocellular carcinoma HepG2 xenografts in nude mice].
Zhou JM; Zhu XF; Liu ZC; Fu LW; Yang XP; Liang YJ; Pan QC
Ai Zheng; 2005 Aug; 24(8):935-9. PubMed ID: 16086869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
